Dandruff Shampoo: Ketoconazole Cut Failures 31%. No Brand Beat Another.
questions people conflate. Does medicated shampoo work? Yes: topical
ketoconazole 2% showed a 31% lower risk of failed clearance compared with
placebo (RR 0.69, 95% CI 0.59 to 0.81, eight studies) at four weeks, and ciclopirox 1%
produced a lower failed-remission rate too (RR 0.79, 95% CI 0.67 to 0.94, eight studies).
Is the expensive one better? There is no published basis for thinking so. Cochrane’s own
conclusion is that limited evidence suggests either of these agents is more effective than any other agent
within the same class — so the choice between two shampoos carrying the same active ingredient
is not an evidence question. Will it keep working? Unknown, and this is the honest gap:
very few studies have assessed symptom clearance for longer periods than four weeks, for a condition
that lasts decades. One more comparison worth knowing: against topical steroids, ketoconazole produced a
similar remission rate (RR 1.17, 95% CI 0.95 to 1.44) with 44% fewer side effects
(RR 0.56, 95% CI 0.32 to 0.96).
The shampoo aisle sells dandruff as a spectrum of severity, priced accordingly. The evidence sorts it
differently: by active ingredient, and then not much further than that.
What actually beat placebo
| Agent | Risk of failed clearance vs placebo | Evidence quality |
|---|---|---|
| Ketoconazole 2% | RR 0.69 (0.59–0.81), 8 studies | Low |
| Ciclopirox 1% | RR 0.79 (0.67–0.94), 8 studies | Moderate |
A risk ratio of 0.69 means the ketoconazole group was 31% less likely to still have unresolved
rash at four weeks. That is a real effect and the confidence interval sits clear of 1.
Note the evidence-quality column, because Cochrane grades it for a reason. The ketoconazole finding is
rated low quality despite having eight studies behind it, and the ciclopirox finding
moderate. The direction is trustworthy; the precision is not as good as the tidy numbers suggest.
The sentence that should change what you buy
From the review’s conclusions:
Ketoconazole and ciclopirox are more effective than placebo, but limited evidence suggests
that either of these agents is more effective than any other agent within the same class.
Read the second half carefully. Once you have chosen a class, the evidence stops helping you
choose within it.
Which means the decision that matters happens on the ingredients panel, not the front of the bottle. Two
shampoos with the same active ingredient at the same concentration are, as far as this evidence goes, the
same purchase at two prices.
The gap nobody mentions: four weeks
Every number above is measured at four weeks of follow-up. And the review says plainly:
Very few studies have assessed symptom clearance for longer periods than four weeks.
Dandruff is not a four-week condition. It is a recurring one that people manage for years.
So the honest summary of the evidence base is narrower than the marketing: we know these agents
clear it over a month. What happens across the following decade — whether it keeps working,
whether it needs to be continuous, whether rotating agents helps — has largely not been studied.
The review adds one more absence: treatment effect on overall quality of life remains unknown.
For a condition whose main burden is visible flakes and discomfort rather than physical harm, that is the
outcome that arguably matters most, and it has not been measured.
Antifungal or steroid?
Both work, and the interesting part is the comparison rather than either one alone.
| Ketoconazole vs topical steroid | Result |
|---|---|
| Remission rate | Similar — RR 1.17 (0.95–1.44), 6 studies |
| Side effects | 44% fewer with ketoconazole — RR 0.56 (0.32–0.96), 8 studies |
A separate Cochrane review, this one on topical anti-inflammatory agents, reached the matching conclusion
from the other direction: comparable rates of total clearance in the steroid and azole groups
(RR 1.11, 95% CI 0.94 to 1.32, eight RCTs, 464 participants).
Two independent reviews, looking at the same comparison from opposite sides, both find no meaningful
difference in how well the two clear it. What separates them is tolerability, and there the antifungal
wins.
The shampoo you stop using has an efficacy of zero
There is a complication to “just buy the ketoconazole”, and it is worth putting on the page because it
cuts against the recommendation.
A crossover study of 40 women with mild to moderate dandruff had each participant use two
shampoos for a week apiece. Subjects preferred the 1% pyrithione zinc conditioning shampoo
over the 2% ketoconazole shampoo by 75% on overall performance. The
investigating dermatologist confirmed it on measurable attributes: hair-combing ease, hair smoothness and
hair frizz or flyaway were all statistically significantly better with the pyrithione zinc conditioning
shampoo.
The authors’ point is about adherence rather than pharmacology: the success of the treatment depends
not only on the ability of the shampoo to control the dandruff but also on patient compliance engendered by
the cosmetic attributes of the shampoo.
Read this study for exactly what it is. Forty participants, one week per arm, and the
outcome measured was preference and hair condition — not clearance of dandruff. It is not
evidence that pyrithione zinc treats dandruff better; it did not test that. What it establishes is that the
better-evidenced agent was the less pleasant one to use, for a condition that requires ongoing treatment.
Which is a real trade-off rather than a tidy one: the strongest placebo-controlled evidence sits with an
agent people liked less, over a four-week evidence horizon, for a condition lasting years. If you have
abandoned a medicated shampoo because you disliked what it did to your hair, that is a recognised failure
mode and not a lack of discipline.
What the evidence implies about the cause, without over-claiming it
This page has deliberately not opened with a story about what dandruff is. It does not need
one.
The treatment that clears it is an antifungal, tested against placebo across sixteen
studies between two agents. That is an observation about what works, and it is the only kind of claim the
sources here support.
It is worth sitting with, though, if your current approach is built on the idea that a flaking scalp is a
dry scalp. Nothing in these reviews tested moisturising, oiling or gentler washing, so this page cannot tell
you those fail. What it can tell you is that the interventions with trial evidence behind them are not
moisturisers.
Buy the ingredient, not the bottle
The two agents with placebo-controlled evidence here are
ketoconazole 2% and ciclopirox 1%. Because Cochrane found only limited
evidence that any agent beats another within its class, the sensible move is to check the active
ingredient panel for one of those two at that strength, and then let price decide. Paying more for a
same-ingredient shampoo is buying something the evidence does not measure.
Ketoconazole 2% shampoo
Ciclopirox 1% shampoo
As an Amazon Associate we earn from qualifying
purchases. We are pointing at two active ingredients rather than a brand because the review explicitly found
limited evidence that any agent outperforms another in the same class — which makes the cheapest
qualifying bottle the rational one.
Frequently Asked Questions
Does ketoconazole shampoo actually work for dandruff?
Yes, against placebo, at four weeks. A Cochrane review found topical ketoconazole 2% showed a 31% lower
risk of failed clearance of rashes compared with placebo, a risk ratio of 0.69 with a 95% confidence interval
of 0.59 to 0.81, across eight studies. Cochrane graded that as low-quality evidence, which does not mean the
finding is wrong; it means the certainty around the size of the effect is weaker than the number looks.
Ciclopirox 1% also beat placebo, with a risk ratio of 0.79, 95% CI 0.67 to 0.94, from eight studies, at
moderate quality.
Is an expensive dandruff shampoo better than a cheap one?
Not on this evidence, provided both contain the same active ingredient at the same strength. The review’s
conclusion states that ketoconazole and ciclopirox are more effective than placebo, but that limited evidence
suggests either of these agents is more effective than any other agent within the same class. That sentence
is doing the work: the class is where the benefit lives, and within a class the studies do not separate the
options. The practical consequence is that the ingredients panel is the part of the bottle worth reading.
Should I use an antifungal or a steroid shampoo?
On clearance they are close; on side effects the antifungal is better tolerated. Compared with steroids,
ketoconazole produced a similar remission rate, risk ratio 1.17 with a 95% confidence interval of 0.95 to
1.44 across six studies, and 44% fewer side effects, risk ratio 0.56 with a 95% CI of 0.32 to 0.96 across
eight studies. A separate Cochrane review of topical anti-inflammatory agents found the same equivalence from
the other side: comparable rates of total clearance in the steroid and azole groups, risk ratio 1.11, 95% CI
0.94 to 1.32, across eight randomised trials and 464 participants.
How long does it keep working?
Nobody has properly established this, and it is the largest hole in the evidence. The review states that
very few studies have assessed symptom clearance for longer periods than four weeks. Every efficacy figure on
this page is a four-week figure. Dandruff, by contrast, is a condition people manage for years, so the
studies cover a small fraction of the timespan that matters to the person buying the shampoo.
Will it improve how I feel about it, not just the flakes?
Unmeasured. The review’s conclusions include the sentence that treatment effect on overall quality of life
remains unknown. That is a striking absence for a condition whose burden is mostly social and psychological
rather than medical, and it is worth naming rather than glossing over: the trials counted rashes cleared, not
whether people felt better about their scalp.
Is dandruff caused by a dry scalp?
The sources on this page do not answer that question directly, and this page will not pretend otherwise.
What they establish is narrower and still useful: the treatments with placebo-controlled trial evidence
behind them are antifungals, across sixteen studies between two agents. No trial reviewed here tested
moisturising or washing less often, so there is no evidence here that those fail either. If your current
approach is built on treating the scalp as dry and it is not working, the point is simply that the
interventions with evidence behind them belong to a different category.
How do I use it?
Follow the product’s own directions, because the trials tested products as labelled rather than a
schedule this page could improve on. What the evidence does suggest is a reasonable review point: efficacy
was measured at four weeks, so four weeks is a fair interval after which to judge whether a given agent is
doing anything for you. If it is not, the review offers a second class with independent placebo-controlled
evidence to try instead.
When should I see a doctor about it?
The trials here studied seborrhoeic dermatitis of the face or scalp, which is a diagnosed condition rather
than a self-assessed one. Flaking that is severe, spreading beyond the scalp, weeping, painful, or not
responding to a properly used antifungal after a reasonable trial is a reason for a clinician to look at it,
partly because several other scalp conditions look similar and are treated differently. Steroids in
particular are a prescription-territory decision, and the side-effect comparison above is one of the reasons
that matters.
Sources
- Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic
dermatitis. Cochrane Database Syst Rev. 2015;(5):CD008138. PMID 25933684. Topical ketoconazole 2% treatment
showed a 31% lower risk of failed clearance of rashes compared with placebo (risk ratio 0.69, 95% CI 0.59 to
0.81, eight studies, low-quality evidence) at four weeks of follow-up; side effects versus placebo were
uncertain (RR 0.97, 95% CI 0.58 to 1.64, six studies). Versus steroids, remission rate was similar (RR 1.17,
95% CI 0.95 to 1.44, six studies) with 44% lower side effects in the ketoconazole group (RR 0.56, 95% CI 0.32
to 0.96, eight studies). Ciclopirox 1% led to a lower failed remission rate than placebo at four weeks (RR
0.79, 95% CI 0.67 to 0.94, eight studies, moderate-quality evidence) with similar rates of side effects (RR
0.9, 95% CI 0.72 to 1.11, four studies, moderate-quality evidence). Authors’ conclusions verbatim:
“Ketoconazole and ciclopirox are more effective than placebo, but limited evidence suggests that either of
these agents is more effective than any other agent within the same class. Very few studies have assessed
symptom clearance for longer periods than four weeks. Ketoconazole produced findings similar to those of
steroids, but side effects were fewer. Treatment effect on overall quality of life remains unknown.” Checked
August 2026 —
PubMed 25933684 - Draelos ZD, Kenneally DC, Hodges LT, Billhimer W, Copas M, Margraf C. A comparison of hair quality and
cosmetic acceptance following the use of two anti-dandruff shampoos. J Investig Dermatol Symp Proc.
2005;10(3):201-4. PMID 16382664. Double-blind cross-over study enrolling 40 women with mild to moderate
dandruff; following a one-week washout with an unmedicated basic cleansing shampoo, all subjects used each of
the two study shampoos for one week. Subjects preferred the 1% pyrithione zinc conditioning shampoo over the
2% ketoconazole shampoo by 75% in terms of overall performance. The dermatologist investigator confirmed the
subject preference by noting that hair-combing ease, hair smoothness, and hair frizz/flyaway were
statistically significantly better in subjects who used the 1% pyrithione zinc conditioning shampoo for one
week. Authors’ framing: the success of the treatment depends not only on the ability of the shampoo to
control the dandruff but also on patient compliance engendered by the cosmetic attributes of the shampoo.
Cited here only for cosmetic acceptability and hair condition, which is what it measured; it did not measure
dandruff clearance, and at 40 participants over one week per arm it is much smaller and shorter than the
Cochrane evidence above. Checked August 2026 —
PubMed 16382664 - Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK,
Verbeek JH. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane
Database Syst Rev. 2014;2014(5):CD009446. PMID 24838779. Steroid treatment resulted in total clearance more
often than placebo in short-term trials of four weeks or less (relative risk 3.76, 95% CI 1.22 to 11.56,
three RCTs, 313 participants). Comparable rates of total clearance in the steroid and azole groups (RR 1.11,
95% CI 0.94 to 1.32, eight RCTs, 464 participants). There may be no difference between steroids and
calcineurin inhibitors in total clearance in the short term (RR 1.08, 95% CI 0.88 to 1.32, two RCTs, 60
participants), with adverse events less common in the steroid group than the calcineurin group in the short
term (RR 0.22, 95% CI 0.05 to 0.89, two RCTs, 60 participants). Lithium was more effective than placebo with
regard to total clearance (RR 8.59, 95% CI 2.08 to 35.52, one RCT, 129 participants) and than azole (RR 1.79,
95% CI 1.10 to 2.90 in short-term treatment, one RCT, 288 participants). Cited here for the independent
steroid-versus-azole comparison. Checked August 2026 —
PubMed 24838779
Every figure on this page is quoted from the two named Cochrane
reviews, including their own grading of evidence quality and their own statements about what has not been
studied, and was checked against them in August 2026. This page summarises published research about
treatments for seborrhoeic dermatitis of the face or scalp. It is not a diagnosis, and a flaking scalp is not
always this condition.
